Published in Lancet on June 11, 2012
ICTUS Study: International Citicoline Trial on Acute Stroke (ICTUS) | NCT00331890
High-dose albumin treatment for acute ischaemic stroke (ALIAS) Part 2: a randomised, double-blind, phase 3, placebo-controlled trial. Lancet Neurol (2013) 1.75
Intranasal Insulin and Insulin-Like Growth Factor 1 as Neuroprotectants in Acute Ischemic Stroke. Transl Stroke Res (2015) 0.96
Neuroprotective properties of citicoline: facts, doubts and unresolved issues. CNS Drugs (2014) 0.95
Hypoxia/Aglycemia-induced endothelial barrier dysfunction and tight junction protein downregulation can be ameliorated by citicoline. PLoS One (2013) 0.94
Stroke: Treatment for acute stroke--the end of the citicoline saga. Nat Rev Neurol (2012) 0.85
Liposomes and nanotechnology in drug development: focus on neurological targets. Int J Nanomedicine (2013) 0.85
Therapeutics targeting the inflammasome after central nervous system injury. Transl Res (2015) 0.83
Mitochondrial function in hypoxic ischemic injury and influence of aging. Prog Neurobiol (2016) 0.83
Stroke in 2012: Major advances in the treatment of stroke. Nat Rev Neurol (2013) 0.82
Citicoline in addictive disorders: a review of the literature. Am J Drug Alcohol Abuse (2014) 0.80
Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke. Theranostics (2016) 0.79
The value of patient selection in demonstrating treatment effect in stroke recovery trials: lessons from the CHIMES study of MLC601 (NeuroAiD). J Evid Based Med (2015) 0.78
The role of citicoline in neuroprotection and neurorepair in ischemic stroke. Brain Sci (2013) 0.78
Molecular Dissection of Cyclosporin A's Neuroprotective Effect Reveals Potential Therapeutics for Ischemic Brain Injury. Brain Sci (2013) 0.78
How effective is citicoline for acute ischaemic stroke? Lancet (2012) 0.78
Cytidine 5'-Diphosphocholine (Citicoline) in Glaucoma: Rationale of Its Use, Current Evidence and Future Perspectives. Int J Mol Sci (2015) 0.77
Emerging issues in acute ischemic stroke. J Neurol (2013) 0.77
Citicoline in stroke and TBI clinical trials. Nat Rev Neurol (2013) 0.77
Quantification of errors in ordinal outcome scales using shannon entropy: effect on sample size calculations. PLoS One (2013) 0.77
ACP Journal Club. Citicoline did not improve recovery at 90 days after moderate-to-severe acute ischemic stroke. Ann Intern Med (2012) 0.76
The role of citicoline in cognitive impairment: pharmacological characteristics, possible advantages, and doubts for an old drug with new perspectives. Clin Interv Aging (2015) 0.76
Flutamide Enhances Neuroprotective Effects of Testosterone during Experimental Cerebral Ischemia in Male Rats. ISRN Neurol (2012) 0.76
Potential efficacy of citicoline as adjunct therapy in treatment of cerebral malaria. Antimicrob Agents Chemother (2013) 0.76
Is aura around citicoline fading? A systemic review. Indian J Pharmacol (2017) 0.75
The choline pathway as a strategy to promote central nervous system (CNS) remyelination. Neural Regen Res (2015) 0.75
Current knowledge on the neuroprotective and neuroregenerative properties of citicoline in acute ischemic stroke. J Exp Pharmacol (2015) 0.75
Interventional neuroradiology of stroke, still not dead. World J Radiol (2013) 0.75
Development and validation of spectrophotometric methods for simultaneous estimation of citicoline and piracetam in tablet dosage form. J Pharm Bioallied Sci (2013) 0.75
Serial plasma choline measurements after cardiac arrest in patients undergoing mild therapeutic hypothermia: a prospective observational pilot trial. PLoS One (2013) 0.75
The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B (2016) 0.75
Boosting Endogenous Resistance of Brain to Ischemia. Mol Neurobiol (2016) 0.75
Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol (2007) 16.81
Thrombectomy within 8 hours after symptom onset in ischemic stroke. N Engl J Med (2015) 6.96
Blood pressure decrease during the acute phase of ischemic stroke is associated with brain injury and poor stroke outcome. Stroke (2004) 3.60
Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke (2006) 3.28
Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke (2003) 3.18
Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke (2008) 2.60
[Clinical features and prognosis of patients with chronic cerebrovascular disease (ICBAR study)]. Rev Neurol (2011) 2.57
Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database. Circ Cardiovasc Imaging (2013) 2.56
Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke (2013) 2.53
European Stroke Initiative Recommendations for Stroke Management-update 2003. Cerebrovasc Dis (2003) 2.35
Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation (2003) 2.30
Increased brain expression of matrix metalloproteinase-9 after ischemic and hemorrhagic human stroke. Stroke (2006) 2.27
An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke. Neurology (2013) 2.26
Microbubble administration accelerates clot lysis during continuous 2-MHz ultrasound monitoring in stroke patients treated with intravenous tissue plasminogen activator. Stroke (2005) 2.24
Poststroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke (2006) 2.22
Tandem internal carotid artery/middle cerebral artery occlusion: an independent predictor of poor outcome after systemic thrombolysis. Stroke (2006) 2.20
Treatment with statins and ischemic stroke severity: does the dose matter? Neurology (2013) 2.12
Patterns and predictors of early risk of recurrence after transient ischemic attack with respect to etiologic subtypes. Stroke (2007) 2.03
[Usefulness of neurosonology in the diagnosis of acute hydrocephalus]. Rev Neurol (2012) 1.92
Higher risk of further vascular events among transient ischemic attack patients with diffusion-weighted imaging acute ischemic lesions. Stroke (2004) 1.91
Diffusion-weighted MR imaging in the acute phase of transient ischemic attacks. AJNR Am J Neuroradiol (2002) 1.83
Prediction of early neurological deterioration using diffusion- and perfusion-weighted imaging in hyperacute middle cerebral artery ischemic stroke. Stroke (2002) 1.80
C-reactive protein predicts further ischemic events in first-ever transient ischemic attack or stroke patients with intracranial large-artery occlusive disease. Stroke (2003) 1.78
The prognostic value of capillary glucose levels in acute stroke: the GLycemia in Acute Stroke (GLIAS) study. Stroke (2008) 1.77
Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain (2007) 1.76
Trevo System: single-center experience with a novel mechanical thrombectomy device. J Neuroimaging (2011) 1.73
Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke (2004) 1.73
The increase of circulating endothelial progenitor cells after acute ischemic stroke is associated with good outcome. Stroke (2007) 1.73
Blood levels of glutamate oxaloacetate transaminase are more strongly associated with good outcome in acute ischaemic stroke than glutamate pyruvate transaminase levels. Clin Sci (Lond) (2011) 1.73
Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol (2007) 1.70
Improving the predictive accuracy of recanalization on stroke outcome in patients treated with tissue plasminogen activator. Stroke (2003) 1.61
The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke (2005) 1.58
Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke (2008) 1.54
Fas system activation in perihematomal areas after spontaneous intracerebral hemorrhage. Stroke (2008) 1.52
Treatment with angiotensin receptor blockers before stroke could exert a favourable effect in acute cerebral infarction. J Hypertens (2010) 1.52
Preventing ventricular dysfunction in pacemaker patients without advanced heart failure: results from a multicentre international randomized trial (PREVENT-HF). Eur J Heart Fail (2011) 1.50
Effect of combined therapy with thrombolysis and citicoline in a rat model of embolic stroke. J Neurol Sci (2006) 1.50
The metabolic syndrome is associated with a higher resistance to intravenous thrombolysis for acute ischemic stroke in women than in men. Stroke (2008) 1.47
Levels of anti-inflammatory cytokines and neurological worsening in acute ischemic stroke. Stroke (2003) 1.45
[In-hospital ischemic strokes in patients admitted to Cardiology and Cardiac Surgery departments. Multi-centre registry]. Med Clin (Barc) (2011) 1.45
Neurology at the airport. J Neurol Neurosurg Psychiatry (2011) 1.45
Comparison of preperfusion and postperfusion magnetic resonance angiography in acute stroke. Stroke (2004) 1.44
[Intravenous tissue-type plasminogen activator for the treatment of acute cerebral ischemia]. Med Clin (Barc) (2003) 1.41
Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest (2005) 1.41
Molecular signatures of vascular injury are associated with early growth of intracerebral hemorrhage. Stroke (2004) 1.41
Thrombolytic therapy for acute ischemic stroke after recent transient ischemic attack. Int J Stroke (2011) 1.40
Importance of cerebral artery recanalization in patients with stroke with and without neurological improvement after intravenous thrombolysis. Stroke (2013) 1.40
Incidence, determinants, and prognostic implications of true pleomorphism of ventricular tachycardia in patients with implantable cardioverter-defribillators: a substudy of the DATAS Trial. Circ Arrhythm Electrophysiol (2010) 1.39
Decompressive surgery in cerebrovenous thrombosis: a multicenter registry and a systematic review of individual patient data. Stroke (2011) 1.39
Usefulness of material recovered from distal embolic protection devices after carotid angioplasty for proteomic studies. J Vasc Interv Radiol (2012) 1.39
Inflammation-mediated damage in progressing lacunar infarctions: a potential therapeutic target. Stroke (2002) 1.36
The risk of paradoxical embolism (RoPE) study: initial description of the completed database. Int J Stroke (2012) 1.32
Neuroprotection by glutamate oxaloacetate transaminase in ischemic stroke: an experimental study. J Cereb Blood Flow Metab (2011) 1.31
Stroke on awakening: looking for a more rational management. Cerebrovasc Dis (2003) 1.30
Matrix metalloproteinase-9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg (2003) 1.27
Toll-like receptors 2 and 4 in ischemic stroke: outcome and therapeutic values. J Cereb Blood Flow Metab (2011) 1.25
Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther (2013) 1.24
Oral citicoline in acute ischemic stroke: an individual patient data pooling analysis of clinical trials. Stroke (2002) 1.24
Treatment-responsive subacute limbic encephalitis and NMDA receptor antibodies in a man. Neurology (2008) 1.23
Role of inflammatory markers in brain ischemia. Curr Opin Neurol (2008) 1.22
Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol (2009) 1.22
Synthesis of lipoxin A4 by 5-lipoxygenase mediates PPARgamma-dependent, neuroprotective effects of rosiglitazone in experimental stroke. J Neurosci (2009) 1.21
Inflammation as therapeutic objective in stroke. Curr Pharm Des (2008) 1.17
Temporal profile of recanalization after intravenous tissue plasminogen activator: selecting patients for rescue reperfusion techniques. Stroke (2006) 1.17
Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 cause potent neuroprotection after experimental stroke through noncompletely overlapping mechanisms. J Cereb Blood Flow Metab (2006) 1.17
Safety and efficacy of intravenous tissue plasminogen activator stroke treatment in the 3- to 6-hour window using multimodal transcranial Doppler/MRI selection protocol. Stroke (2005) 1.16
Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia. Am J Hum Genet (2013) 1.15
Ischemic preconditioning reveals that GLT1/EAAT2 glutamate transporter is a novel PPARgamma target gene involved in neuroprotection. J Cereb Blood Flow Metab (2007) 1.13
The role of the cerebral capillaries in acute ischemic stroke: the extended penumbra model. J Cereb Blood Flow Metab (2013) 1.12
Acute hyperglycemia state is associated with lower tPA-induced recanalization rates in stroke patients. Stroke (2005) 1.12
A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med (2006) 1.12
Decreased corticospinal tract fractional anisotropy predicts long-term motor outcome after stroke. Stroke (2013) 1.12
Age determines the effects of blood pressure lowering during the acute phase of ischemic stroke: the TICA study. Hypertension (2009) 1.11
A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett (2002) 1.11